Alzheimer disease is a devastating chronic disease without adequate therapy. More than 10 years ago, it was demonstrated in transgenic mouse models that vaccination may be a novel, disease-modifying therapy for Alzheimer. Subsequent clinical development has been a roller-coaster with some positive and many negative news. Here, we would like to summarize evidence that next generation vaccines optimized for old people and focusing on patients with mild disease stand a good chance to proof efficacious for the treatment of Alzheimer
Vaccinations with amyloid-β peptide (AB) can dramatically reduce amyloid deposition in a transgenic ...
Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vacci...
Vaccinations with amyloid-β peptide (AB) can dramatically reduce amyloid deposition in a transgenic ...
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic ne...
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic ne...
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic ne...
The cause of Alzheimer's disease is still unknown, but the disease is distinctively characterized by...
Alzheimer’s disease (AD) is an incurable, progressive, neurodegenerative disorder affecting over 5 m...
INTRODUCTION Alzheimer's disease looms as a profound and growing threat to future human health. T...
The cause of Alzheimer’s disease is still unknown, but the disease is distinctively characterized by...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized pathologi...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized pathologi...
Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vacci...
Vaccinations with amyloid-β peptide (AB) can dramatically reduce amyloid deposition in a transgenic ...
Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vacci...
Vaccinations with amyloid-β peptide (AB) can dramatically reduce amyloid deposition in a transgenic ...
Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vacci...
Vaccinations with amyloid-β peptide (AB) can dramatically reduce amyloid deposition in a transgenic ...
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic ne...
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic ne...
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic ne...
The cause of Alzheimer's disease is still unknown, but the disease is distinctively characterized by...
Alzheimer’s disease (AD) is an incurable, progressive, neurodegenerative disorder affecting over 5 m...
INTRODUCTION Alzheimer's disease looms as a profound and growing threat to future human health. T...
The cause of Alzheimer’s disease is still unknown, but the disease is distinctively characterized by...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized pathologi...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized pathologi...
Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vacci...
Vaccinations with amyloid-β peptide (AB) can dramatically reduce amyloid deposition in a transgenic ...
Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vacci...
Vaccinations with amyloid-β peptide (AB) can dramatically reduce amyloid deposition in a transgenic ...
Previously, our lab was the first to report the use of antigen-sensitized dendritic cells as a vacci...
Vaccinations with amyloid-β peptide (AB) can dramatically reduce amyloid deposition in a transgenic ...